SU5402 is a potent inhibitor of FGFR, VEGFR, and PDGFR. It has been used in many studies to inhibit cancer cell growth, or modulate stem cell phenotypes, including maintenance of mouse ESCs, or inducing generation of functional human nociceptors from human ESCs/iPSCs when combined with LDN193189/BMP inhibitor, SB431542/TGFβ inhibitor, CHIR99021/GSK3 inhibitor, and DAPT/Notch inhibitor. 

How to Use:

• In vitro: SU5402 is typically used at 10 µM final concentration.
• In vivo: SU5402 could be used via subcutaneous dosing to mice at 25 mg/kg once per day.

Reference:

1. 1. Mohammadi M, et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. (1997) Science 276(5314):955-60.
2. 2. Sun L., et al. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. (1999) J Med Chem.42(25):5120-30
3. 3. Tanaka Y., et al. FGF-induced vesicular release of Sonic hedgehog and retinoic acid in leftward nodal flow is critical for left-right determination. (2005) Nature 435(7039):172-7
4. 4. Chambers SM, et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. (2012) Nature Biotechnology 30, 715-720.
5. 5. Ying QL, et al. The ground state of embryonic stem cell self-renewal. (2008) Nature 453, 519–523
6. 6. Nechiporuk A, et al. FGF-dependent mechanosensory organ patterning in zebrafish. (2008) Science 320(5884):1774-7.